COLUMBUS, Ohio, Sept. 18 Roxane Laboratories, Inc.announced today the approval of their Abbreviated New Drug Application forProtriptyline HCl Tablets, USP, 5mg and 10mg. The product is available inbottles of 100 tablets for immediate shipment to wholesalers and pharmaciesnationwide.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )
Roxane Laboratories' Protriptyline HCl Tablets, USP are AB rated toVIVACTIL(R) (protriptyline HCl). Annual sales of VIVACTIL(R) (protriptylineHCl) Tablets are approximately $11.3 Million(1).
Full prescribing information for Protriptyline HCl Tablets, USP isavailable on the Roxane Laboratories website at www.Roxane.com or upon requestby calling Roxane Laboratories Technical Product Information at1.800.962.8364.
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 squarefoot manufacturing and laboratory facility. The facility spans 70 acres andcurrently employs over 1,000 people. Currently, Roxane Laboratories marketsover 75 medications in nearly 250 package sizes, focusing on an expanding lineof Multisource pharmaceutical products including: bulk and unit-dose liquidsand solids; coated, sustained-release and controlled-release tablets; nasalsprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc., is a subsidiary of Boehringer IngelheimCorporation, based in Ridgefield, CT and a member of the Boehringer Ingelheimgroup of companies.
About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the USheadquarters to seven subsidiaries and a member of the Boehringer Ingelheimgroup of companies.
The Boehringer Ingelheim group is one of the world's 20 leadingpharmaceutical companies. Headquartered in Ingelheim, Germany, it operatesglobally with 135 affiliates in 47 countries and approximately 39,800employees. Since it was founded in 1885, the family-owned company has beencommitted to researching, developing, manufacturing and marketing novelproducts of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9billion euro) while spending approximately one-fifth of net sales in itslargest business segment, Prescription Medicines, on research and development.
For more information on Boehringer Ingelheim, please visithttp://us.boehringer-ingelheim.com.
(1) IMS MAT dollar sales ending 3/2008
VIVACTIL(R) is a registered trademark of Duramed Pharmaceuticals, Inc.
SOURCE Roxane Laboratories, Inc.